Search clinical trials for: DTG ABC/3TC DTG TDF/FTC EVG/cobi/TDF/FTC RAL TDF/FTC

Total 307 results

Juan A. Arnaiz

Unknown

Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (RALAM)

AIDS

Spain
Fundacion SEIMC-GESIDA

Completed

A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (DREAM)

HIV Infections

Spain
The HIV Netherlands Australia Thailand Research...
National Health Security Office, Thailand; Swiss HIV Cohort Study

Completed

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

HIV Infections

Thailand
International Antiviral Therapy Evaluation Center
Gilead Sciences

Completed

PREventing Progression of Adipose Tissue Redistribution

HIV Infections

Netherlands
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
University of Washington
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

The Kampala Women's Bone Study

Hypoestrogenism | Bone Demineralization | Subclinical Kidney Injury | Bone Microarchitecture

Uganda
The Institute of Molecular and Translational Medicine...

Completed

Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients

Colorectal Cancer | Circulating Tumor Cell

Czechia
Yale University

Completed

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

HIV Infections

United States
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
University of California, Los Angeles
Gilead Sciences

Completed

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) (UCLACAREMITO)

HIV/AIDS | Mitochondrial Alteration | Antiviral Toxicity | Antiviral Drug Adverse Reaction

United States
The Institute of Molecular and Translational Medicine...

Completed

Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

Non Small Cell Lung Cancer | Circulating Tumor Cell

Czechia
Prism Health North Texas
Merck Sharp & Dohme LLC

Withdrawn

Doravirine and Weight Gain in Antiretroviral Naive (DAWN)

Obesity | Metabolic Syndrome | Body Weight Changes | Human Immunodeficiency Virus | Fasting | Minority Health | ART | BMD

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Auritec Pharmaceuticals
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

Human Immunodeficiency Virus (HIV) Prophylaxis

United States
Janssen Scientific Affairs, LLC

Completed

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

HIV-1

United States
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
The HIV Netherlands Australia Thailand Research...
Mylan Laboratories

Completed

Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz

HIV

Thailand
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load (EASIER)

HIV Infections

France
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Infection, Human Immunodeficiency Virus

United States, Canada, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
ViiV Healthcare

Active, not recruiting

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

HIV Infections

Thailand, Kenya, South Africa
ANRS, Emerging Infectious Diseases
University of KwaZulu; Africa Centre For Health and Population Studies

Completed

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (TasP)

HIV Infection

South Africa
The HIV Netherlands Australia Thailand Research...
Police General Hospital; Faculty of Medical Sciences, Radboud University of... and other collaborators

Completed

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

HIV

Thailand
Azienda Ospedaliera San Gerardo di Monza
Gilead Sciences

Completed

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (SWEAR)

Quality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/Anxiety

Italy
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

HIV Infections

United States, Germany, Spain, Taiwan, United Kingdom, Canada, Belgium, France, Italy, South Africa, Argentina, Russian Federation, Denmark, Mexico, China, Sweden, Brazil
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
Pedro Cahn
Merck Sharp & Dohme LLC

Unknown

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients (ARTE)

Chronic Infection With HIV

Argentina
Peking Union Medical College

Unknown

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

AIDS/HIV PROBLEM

China
International AIDS Vaccine Initiative

Completed

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

HIV Infection

Uganda
International AIDS Vaccine Initiative

Completed

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

HIV Infections

Kenya
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
Gilead Sciences

Completed

Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial (COOL)

HIV Infections

France
Felipe Garcia

Completed

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

HIV-1 Infection

Spain
University of Washington
National Institute of Mental Health (NIMH); United States Agency for International... and other collaborators

Completed

Partners Demonstration Project of PrEP and ART

HIV Infection

Kenya, Uganda
Duke University

Completed

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (PHI04)

HIV

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

HIV Infections

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

HIV Infections | Arthralgia | Infection, Human Immunodeficiency Virus

Spain, Russian Federation
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
HIV Prevention Trials Network

Completed

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

HIV

United States
Duke University
The Emmes Company, LLC

Recruiting

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana (BMS02)

HIV Infections | Lactating Women on Select DOI | Breastmilk Fed Infants of Mothers on Select DOI

South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

United States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (DETOX)

HIV Infections

Spain
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study (PrIMO)

Pregnancy Related | HIV Prevention | Pre-exposure Prophylaxis

Malawi
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
Gilead Sciences

Completed

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Mahidol University

Unknown

Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz

Bone Density

Thailand

3

Subscribe